This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spenlehauer, C.
Right arrow Articles by Moog, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spenlehauer, C.
Right arrow Articles by Moog, C.

 Previous Article  |  Next Article 

Journal of Virology, March 2001, p. 2235-2245, Vol. 75, No. 5
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.5.2235-2245.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Antibody-Mediated Neutralization of Primary Human Immunodeficiency Virus Type 1 Isolates: Investigation of the Mechanism of Inhibition

Catherine Spenlehauer,dagger André Kirn, Anne-Marie Aubertin, and Christiane Moog*

INSERM U74, Institut de Virologie, 67000 Strasbourg, France

Received 8 May 2000/Accepted 22 November 2000

Human immunodeficiency virus type 1 (HIV-1) neutralization occurs when specific antibodies, mainly those directed against the envelope glycoproteins, inhibit infection, most frequently by preventing the entry of the virus into target cells. However, the precise mechanisms of neutralization remain unclear. Previous studies, mostly with cell lines, have produced conflicting results involving either the inhibition of virus attachment or interference with postbinding events. In this study, we investigated the mechanisms of neutralization by immune sera and compared the inhibition of peripheral blood mononuclear cells (PBMC) infection by HIV-1 primary isolates (PI) with the inhibition of T-cell line infection by T-cell line-adapted (TCLA) strains. We followed the kinetics of neutralization to determine at which step of the viral cycle the antibodies act. We found that neutralization of the TCLA strain HIV-1MN/MT-4 required an interaction between antibodies and cell-free virions before the addition of MT-4 cells, whereas PI were neutralized even after adsorption onto PBMC. In addition, the dose-dependent inhibition of HIV-1MN binding to MT-4 cells was strongly correlated with serum-induced neutralization. In contrast, neutralizing sera did not reduce the adhesion of PI to PBMC. Postbinding inhibition was also detected for HIV-1MN produced by and infecting PBMC, demonstrating that the mechanism of neutralization depends on the target cell used in the assay. Finally, we considered whether the different mechanisms of neutralization may reflect the recognition of qualitatively different epitopes on the surface of PI and HIV-1MN or whether they reflect differences in virus attachment to PBMC and MT-4 cells.


* Corresponding author. Mailing address: INSERM U74, Institut de Virologie, 3 rue Koeberlé, 67000 Strasbourg, France. Phone: (33)-(0)3-88-56-63-00. Fax: (33)-(0)3-88-56-63-03. E-mail: c.moog{at}viro-ulp.utrasbg.fr.

dagger Present address: Weill Medical College of Cornell University, Department of Microbiology and Immunology, New York, NY 10021.


Journal of Virology, March 2001, p. 2235-2245, Vol. 75, No. 5
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.5.2235-2245.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Haim, H., Steiner, I., Panet, A. (2007). Time Frames for Neutralization during the Human Immunodeficiency Virus Type 1 Entry Phase, as Monitored in Synchronously Infected Cell Cultures. J. Virol. 81: 3525-3534 [Abstract] [Full Text]  
  • Zhang, R., Lifson, J. D., Chougnet, C. (2006). Failure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactions. Blood 107: 1989-1995 [Abstract] [Full Text]  
  • Popovic, M., Tenner-Racz, K., Pelser, C., Stellbrink, H.-J., van Lunzen, J., Lewis, G., Kalyanaraman, V. S., Gallo, R. C., Racz, P. (2005). Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 102: 14807-14812 [Abstract] [Full Text]  
  • Forthal, D. N., Landucci, G., Phan, T. B., Becerra, J. (2005). Interactions between Natural Killer Cells and Antibody Fc Result in Enhanced Antibody Neutralization of Human Immunodeficiency Virus Type 1. J. Virol. 79: 2042-2049 [Abstract] [Full Text]  
  • Burrer, R., Haessig-Einius, S., Aubertin, A.-M., Moog, C. (2003). Polyclonal Immunoglobulin G from Patients Neutralizes Human Immunodeficiency Virus Type 1 Primary Isolates by Binding Free Virions, but without Interfering with an Initial CD4-Independent Attachment of the Virus to Primary Blood Mononuclear Cells. J. Virol. 77: 11385-11397 [Abstract] [Full Text]  
  • Ketas, T. J., Frank, I., Klasse, P. J., Sullivan, B. M., Gardner, J. P., Spenlehauer, C., Nesin, M., Olson, W. C., Moore, J. P., Pope, M. (2003). Human Immunodeficiency Virus Type 1 Attachment, Coreceptor, and Fusion Inhibitors Are Active against both Direct and trans Infection of Primary Cells. J. Virol. 77: 2762-2767 [Abstract] [Full Text]  
  • Herrera, C., Spenlehauer, C., Fung, M. S., Burton, D. R., Beddows, S., Moore, J. P. (2002). Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site. J. Virol. 77: 1084-1091 [Abstract] [Full Text]  
  • Klasse, P. J., Sattentau, Q. J. (2002). Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83: 2091-2108 [Abstract] [Full Text]  
  • Giannecchini, S., Isola, P., Sichi, O., Matteucci, D., Pistello, M., Zaccaro, L., Del Mauro, D., Bendinelli, M. (2002). AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Failure To Protect and Possible Enhancement of Challenge Infection by Four Cell-Based Vaccines Prepared with Autologous Lymphoblasts. J. Virol. 76: 6882-6892 [Abstract] [Full Text]  
  • Burrer, R., Salmon-Ceron, D., Richert, S., Pancino, G., Spiridon, G., Haessig, S., Roques, V., Barre-Sinoussi, F., Aubertin, A.-M., Moog, C. (2001). Immunoglobulin G (IgG) and IgA, but also Nonantibody Factors, Account for In Vitro Neutralization of Human Immunodeficiency Virus (HIV) Type 1 Primary Isolates by Serum and Plasma of HIV-Infected Patients. J. Virol. 75: 5421-5424 [Abstract] [Full Text]